This company develops an advanced nasal drug delivery platform designed to reinforce the body's first line of defense against airborne pathogens and allergens. Their technology optimizes absorption and extends contact time within the nasal passage, offering faster and more consistent therapeutic results than traditional oral delivery methods. The platform focuses on creating precision nasal sprays engineered for proactive health prevention and sustained efficacy.
Funding
Funding not disclosed
FLFounders
Product
Problem
Respiratory infections, such as the cold, flu, and COVID-19, are often initiated in the nasal passages by airborne pathogens. While the nasal passages have natural defenses, these are often insufficient to prevent infection.
Solution
Akita Biosciences develops intranasal therapies designed to enhance the body's innate immune response to airborne pathogens. Their nasal sprays utilize rapid absorption technology to deliver therapeutic agents directly into the bloodstream via the nasal passages, bolstering defenses against respiratory infections. By amplifying the body's natural defense system, Akita Biosciences aims to trigger a more robust and effective immune response, generating a broad-spectrum defense against a wide range of respiratory infections. This non-invasive method offers rapid therapeutic benefits, typically occurring within minutes.
Target Audience
The primary target audience includes individuals seeking to proactively defend against airborne respiratory infections, as well as those looking for a non-invasive method of immune support.
Features
- Nasal spray formulation for direct delivery of therapeutic agents to the nasal passages.
- Rapid absorption technology enabling quick entry into the bloodstream.
- Enhancement of the body's innate immune response.
- Broad-spectrum immune response against various respiratory infections.
- Non-invasive administration.